The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs-Reference-Cited by-同舟云学术

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

Published:2015-01-26 Issue:7 Volume:21 Page:1628-1638
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Boi Michela,Gaudio Eugenio,Bonetti Paola,Kwee Ivo,Bernasconi Elena,Tarantelli Chiara,Rinaldi Andrea,Testoni Monica,Cascione Luciano,Ponzoni Maurilio,Mensah Afua Adjeiwaa,Stathis Anastasios,Stussi Georg,Riveiro María Eugenia,Herait Patrice,Inghirami Giorgio,Cvitkovic Esteban,Zucca Emanuele,Bertoni Francesco

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors;European Journal of Medicinal Chemistry;2024-09

2. Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC;Cell Communication and Signaling;2024-08-27

3. Targeting CD25+ lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents;British Journal of Haematology;2024-07-30

4. BET inhibition revealed varying MYC addiction mechanisms independent of gene alterations in aggressive B-cell lymphomas.;2024-07-22

5. Identifying Diagnostic Markers and Constructing Predictive Models for Oxidative Stress in Multiple Sclerosis;International Journal of Molecular Sciences;2024-07-10